Bringing new therapy options to the hemophilia community

Thrombosis Research

Volumn 131, Issue SUPPL.2, 2013, Pages

  Bensen Kennedy, Debra ^a  

^a CSL Behring   (United States)

Author keywords

Factor VIIa; Factor VIII; Fusion protein technology; Hemophilia; Recombinant albumin; Recombinant albumin fusion; Single chain factor VIII

Indexed keywords

BLOOD CLOTTING FACTOR; HYBRID PROTEIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR VIIA WITH ALBUMIN; RECOMBINANT SINGLE CHAIN FACTOR VIII; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WARFARIN;

AREA UNDER THE CURVE; BLOOD CLOTTING; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HALF LIFE TIME; HEMOPHILIA A; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ALBUMINS; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; HEMOPHILIA A; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84875549788     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(13)70153-1     Document Type: Conference Paper

References (15)

1. SW Pipe The hope and reality of long-acting hemophilia products Am J Hematol 87 Suppl 1 2012 S33 S39
2. CA Leissinger The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors Am J Hematol 87 Suppl 1 2012 S23 S26
3. M Franchini, G Lippi Immune tolerance induction for patients with severe hemophilia A: a critical literature review J Thromb Thrombolysis 32 2011 439 447
4. A Srivastava, AK Brewer, EP Mauser-Bunschoten et al. Guidelines for the management of hemophilia Haemophilia 19 1 2013 e1 47 10.1111/j.1365-2516.2012. 02909.x [Epub ahead of print].
5. D Lillicrap von Willebrand disease-phenotype versus genotype: deficiency versus disease Thromb Res 120 Suppl 1 2007 S11 S16
6. S Dasgupta, Y Repessé, J Bayry et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors Blood 109 2007 610 612 (Pubitemid 46105959)
7. CJ van Schooten, S Shahbazi, E Groot et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo Blood 112 2008 1704 1712
8. S Schmidbauer, R Witzel, J Kreuter et al. Physico-chemical characterization of recombinant single chain FVIII Hämostaeseologie 32 2012 A41 [Abstract P2-29].
9. SB Zollner, E Raquet, J Müller-Cohrs et al. Preclinical efficacy and safety of CSL627 novel recombinant, single-chain FVIII Hämostaeseologie 32 2012 A38 [Abstract P2-19].
10. JM Lusher, HR Roberts, G Davignon et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group Haemophilia 4 1998 790 798 (Pubitemid 28561369)
11. E Erhardtsen Pharmacokinetics of recombinant activated factor VII (rFVIIa) Semin Thromb Hemost 26 2000 385 391
12. U Kronthaler, S Schmidbauer, U Liebing et al. Prolonged half-life of recombinant factor VIIa fusion protein-single dose study in rabbits J Thromb Haemost 5 Suppl 2 2009 PP-TH-561
13. S Schulte, T Weimer, W Wormsbächer et al. Prolonged in vivo half-life of FVIIa by fusion to albumin Blood 110 2007 Abstract 3142.
14. T Weimer, W Wormsbächer, U Kronthaler et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin Thromb Haemost 99 2008 659 667 (Pubitemid 351694221)
15. HJ Metzner, T Weimer, S Schulte Half-life extension by fusion to recombinant albumin R Kontermann Therapeutic proteins. Strategies to modulate their plasma half-life 2012 Wiley-VCH Verlag & Co. Weinheim 223 247